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Age-related macular degeneration (AMD) is the leading cause of
blindness in the elderly. While the histopathology of the different
disease stages is well characterized, the cause underlying the pro-
gression, from the early drusen stage to the advanced macular
degeneration stage that leads to blindness, remains unknown.
Here, we show that photoreceptors (PRs) of diseased individuals
display increased expression of two key glycolytic genes, sugges-
tive of a glucose shortage during disease. Mimicking aspects of
this metabolic profile in PRs of wild-type mice by activation of
the mammalian target of rapamycin complex 1 (mTORC1) caused
early drusen-like pathologies, as well as advanced AMD-like pa-
thologies. Mice with activated mTORC1 in PRs also displayed other
early disease features, such as a delay in photoreceptor outer seg-
ment (POS) clearance and accumulation of lipofuscin in the retinal-
pigmented epithelium (RPE) and of lipoproteins at the Bruch’s
membrane (BrM), as well as changes in complement accumulation.
Interestingly, formation of drusen-like deposits was dependent on
activation of mTORC1 in cones. Both major types of advanced
AMD pathologies, including geographic atrophy (GA) and neovas-
cular pathologies, were also seen. Finally, activated mTORC1 in PRs
resulted in a threefold reduction in di-docosahexaenoic acid (DHA)–
containing phospholipid species. Feeding mice a DHA-enriched
diet alleviated most pathologies. The data recapitulate many as-
pects of the human disease, suggesting that metabolic adaptations
in photoreceptors could contribute to disease progression in AMD.
Identifying the changes downstream of mTORC1 that lead to ad-
vanced pathologies in mouse might present new opportunities to
study the role of PRs in AMD pathogenesis.
AMD | photoreceptors | geographic atrophy | wet AMD | photoreceptor
metabolism
Age-related macular degeneration (AMD) is the leadingcause of irreversible vision loss in the elderly (1, 2). Early
disease stages are defined by the formation of drusen, which are
lipid-rich deposits located between the retinal-pigmented epi-
thelium (RPE) and the underlying Bruch’s membrane (BrM) (1).
Advanced disease stages are characterized by confluent RPE
atrophy, referred to as geographic atrophy (GA), and/or edemas
that result from choroidal and/or retinal neovascularization (1).
Both advanced stages cause blindness through extensive secondary
loss of photoreceptors (PRs). Notably, 20% of individuals with
early stage drusen progress to the advanced disease forms. Al-
though the RPE is the primary cell type affected in advanced
AMD, what causes disease progression remains unclear (2).
Two factors that contribute to drusen genesis and disease
progression in AMD are genetic variations in genes of the innate
immune system and poor diet (3–7). Dysregulation of comple-
ment components such as C3 and CFH, which are central to the
activation and inhibition of the complement system, respectively,
is thought to contribute to RPE atrophy (3). Excessive con-
sumption of saturated dietary fats also influences drusen for-
mation as drusen are rich in lipoproteins that are partially derived
from the circulation (8). In contrast, foods enriched in poly-
unsaturated fatty acids, such as the omega-3 fatty acid docosahex-
aenoic acid (DHA), have been linked through many epidemiological
studies to a risk reduction for advanced AMD (9, 10). Although
DHA is highly enriched in photoreceptor outer segments (POSs),
the mechanism of protection remains unknown (11).
The role of PRs in disease pathogenesis remains to be deter-
mined as PRs have been associated with both the early and late
disease stages (8, 12–14). For example, macular translocation
procedures revealed that PRs can cause the late disease stage of
GA. Patients whose retina was rotated to move macular cones
away from an area of GA to an area of healthy RPE redeveloped
GA where the cones were translocated (12, 13). Similarly, analyses
on the distribution of soft drusen and subretinal drusen deposits
revealed that their preferential location mirrors the density of
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cones and rods, respectively (8, 14). In both cases, the high and
differential metabolic demands of cones and rods are thought to
contribute to disease pathogenesis (8, 12–14). However, whether
the metabolic demands of PRs differ in individuals with AMD has
not been investigated. This question is particularly pertinent since
glucose shortage in PRs of AMD patients has been predicted by
several models of disease pathogenesis. For example, the mito-
chondrial dysfunction seen in RPE cells of AMD patients has
been proposed to reduce glucose transfer from the RPE to PRs.
The idea here is that, to compensate for the energy shortfall
caused by dysfunctional mitochondria, the RPE starts utilizing
glucose itself, rather than providing it to PRs and use PR-derived
lactate (15). The finding of a lipid wall at the BrM that forms
during the early drusen stage of the disease (oil spill model) is also
predicted to cause a glucose shortage in PRs as this hydrophobic
barrier should reduce the transfer of hydrophilic molecules like
glucose from the choroidal vascular to the RPE and thus PRs (8).
These models are not mutually exclusive; rather they represent
sequential disease stages that once superimposed could compound
the glucose shortage in PRs even more. Thus, if these models are
correct, one would expect to find adaptive changes in PRs of
AMD patients that allow PRs to cope with a glucose shortfall.
Here, we show that the expression of two genes that are
characteristic of PR metabolism and cell growth (16–20), namely
pyruvate kinase muscle isozyme M2 (Pkm2) and hexokinase-2
(Hk2), is increased in individuals with AMD. HK2 improves
glucose retention and PKM2 allows for a more efficient diversion
of glycolytic intermediates into the pentose phosphate pathway
(PPP). Because the PPP promotes cellular NADPH synthesis
and NADPH is a reducing agent that is also required for fatty
acid synthesis, the PPP helps reduce cellular oxidative stress and
maintain the renewal of the lipid-rich POSs (16, 17, 19). HK2
and PKM2 have both been implicated during secondary cone
death in retinitis pigmentosa where cone death was found to be
in part due to a glucose shortage in cones (18, 21, 22). One of the
adaptive responses of cones in retinitis pigmentosa is to increase
the expression of these two proteins through increased activity of
the mammalian target of rapamycin complex 1 (mTORC1), a
key regulator of cell metabolism and cell growth (22–25). Loss of
mTORC1 activity or HK2 accelerates cone death in retinitis
pigmentosa while constitutive activation of mTORC1 promotes
cone survival (18, 22). Similarly, loss of mTORC1 activity in the
sodium iodate model of GA accelerates PR death (26). There-
fore, to mimic the adaptive responses seen in PRs of AMD pa-
tients and study their effect on retinal and RPE health, we
generated a mouse model with constitutive activation mTORC1
in PRs of wild-type mice. This was achieved by deletion of the
tuberous sclerosis complex 1 (Tsc1) gene, a negative regulator of
mTORC1 (27). We found an age- and mTORC1-dependent onset
of advanced AMD pathologies, including GA and neovascular
pathologies, at a frequency similar to that seen in humans (2).
Mice with activated mTORC1 also displayed early disease fea-
tures, such as accumulation of lipoproteins at the BrM (8, 14) and
changes in complement C3 and CFH deposition (3). These
changes occurred uniformly across the tissue independent of the
presence of any advanced pathology. Finally, we also found a re-
duction in 1,2-docosahexanoyl-sn-glycero-3-phospholipid species
in retinas of these mice. Feeding mice a DHA-enriched diet al-
leviated most pathologies (9, 10). The data mimic most aspects of
the human disease, suggesting that metabolic adaptations in PRs
could be a contributing factor for disease progression in AMD.
Results
HK2 and PKM2 Expression Are Increased in PRs of AMD Patients.HK2
and PKM2 are two glycolysis enzymes that are generally asso-
ciated with cell growth during development, as well as tumori-
genesis, as they promote progrowth pathways such as the PPP (28,
29). While normally not expressed in most postmitotic neurons,
both genes are a key signature of PR metabolism (16–20). This is
because PRs are in a constant phase of cell growth, due to the
need to replace the daily shed POSs. Both genes thus play an
important role in POS renewal, function, and survival, in partic-
ular under nutrient stress (16–22). To determine whether PR
metabolism differs in individuals with AMD, we analyzed the
expression of these two key metabolic genes in human donor eyes
with or without AMD. On retinal sections, we found increased
expression of PKM2 and HK2 in PRs of AMD patients (n = 3),
with the highest increase found in cones (Fig. 1A and SI Appendix,
Fig. S1 A and B). Interestingly, expression in nondiseased retinas
was quite low for PKM2 as those sections required up to five times
longer exposure to the histochemical reagent in order for a strong
signal to emerge (Fig. 1A). To allow for a more linear comparison
between samples, we repeated the experiments using immuno-
fluorescence (SI Appendix, Fig. S1A). A twofold scaling of the
signal between nondiseased and diseased tissue was sufficient to
reveal a PR signal in nondiseased tissue without causing over-
exposure of the signal in diseased retinas. Interestingly, the ex-
pression of both genes in mouse has been shown to decline with
age (SI Appendix, Fig. S1C) (18, 30). This could in part account for
the stark difference in signal intensity seen between diseased and
nondiseased individuals. In summary, the data show that levels of
HK2 and PKM2 increase in PRs of individuals with AMD, sug-
gesting that glucose availability is reduced in diseased individuals.
rodTsc1−/− Mice Develop Advanced AMD Pathologies. We previously
showed that nutrient-deprived cones have higher mTORC1 ac-
tivity and that further activation of mTORC1 promotes the
survival of nutrient-deprived cones in part through increased
expression HK2 and PKM2 (21, 22, 26). To determine the effect
of such metabolic changes on retinal and RPE health in wild-
type mice, we constitutively activated mTORC1 in rods by de-
letion of the Tsc1 gene (henceforth referred to as rodTsc1−/−) using
the Cre-lox system (31). Increased mTORC1 activity was con-
firmed by immunofluorescence and Western blot analyses for
phosphorylated ribosomal protein S6 (p-S6) (Fig. 1 B and C) (24).
Similarly, changes in PR metabolism were confirmed by quanti-
fying retinal PKM2, lactate, and NADPH levels (Fig. 1 C–E).
To determine whether rodTsc1−/− mice develop advanced
AMD-like pathologies, we followed the mice over a period of 18
mo (18M) by funduscopy and fluorescein angiography (Fig. 2
and SI Appendix, Fig. S2). We found, at 2M, migration and ac-
cumulation of microglia into the subretinal space and, at 4M,
formation of retinal folds, some of which were filled with
microglia (SI Appendix, Fig. S3) (32). Flat mount and section
analyses revealed highly autofluorescent RPE cells opposing
these folds (Fig. 3 A and B), which in mice may be a direct
consequence of acutely compromised or lost RPE cells (33, 34).
GA was seen in 5% of mice at 6M and 25% of mice at 18M
(Fig. 2C). Interestingly, while GA did also overlap with areas of
retinal folds, the presence of these folds was not required for GA
to develop. Generally, pathologies worsened within the same
animal with age (SI Appendix, Fig. S2). To confirm that areas of
GA correlate with regional PR atrophy and that RPE atrophy
precedes PR atrophy, we compared the RPE and corresponding
retina by flat mount analyses (Fig. 3 A–C), identified interme-
diate RPE pathologies (Fig. 3D), and performed semithin sec-
tioning through regions of GA that were identified by optical
coherence tomography (OCT) (Fig 3 E and F).
Neovascular pathologies reaching a frequency of 7% by 18M
were seen less frequently than GA (Fig. 2C) although most co-
incided with regions of GA. While we readily detected retinal
neovascular pathologies on semithin sections (Fig. 3F), choroidal
neovascular pathologies were not evident on RPE flat mounts.
However, given the overall low frequency of neovascular pa-
thologies, we cannot conclude that choroidal neovascular pa-
thologies do not occur. Except for the accumulation of subretinal
Cheng et al. PNAS | June 9, 2020 | vol. 117 | no. 23 | 13095
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microglia, none of the heterozygous rodTsc1+/− mice nor any of
the Cre– littermate control mice (rodTsc1+/+) developed ad-
vanced pathologies (Fig. 2 B and C). Consistent with this, acti-
vation of mTORC1 and the increase in PKM2 expression levels
were both minimal in rodTsc1+/− mice (Fig. 1C).
To determine if RPE stress and atrophy also occurred outside
regions of GA, we determined the percentage of polynucleated
RPE cells and measured changes in RPE cell size in non-GA
areas. At 18M, we found a significant increase in polynucleated
and enucleated as well as hypertrophic RPE cells (Fig. 3G). The
data indicate that loss of Tsc1 in rods contributes to a widespread
RPE pathology that precipitates to regional GA in some animals.
We therefore determined if overall PR survival and function
were perturbed. Consistent with a widespread RPE pathology,
we found a small decrease in the thickness of the PR layer at
18M (SI Appendix, Fig. S4A). This decrease may also explain the
less prominent appearance of retinal folds with age (SI Appendix,
Fig. S2) as they begin to flatten with the loss of PRs. In-
terestingly, rod a-wave amplitudes were higher in rodTsc1−/− mice
at early time points but declined to the littermate control am-
plitudes by 18M (SI Appendix, Fig. S4B). The early higher am-
plitude is in line with our previous findings where loss of HK2
leads to a reduction of the scotopic response and a reduction in
retinal lactate and NADPH levels (18). Thus, the early higher
amplitude may reflect higher energy availability. Alternatively,
increased transcription or translation of phototransduction genes
due to increased PKM2 expression or increased mTORC1 activity,
respectively, could also account for higher a-wave amplitudes in
rodTsc1−/− mice (16, 24). Further studies are warranted to de-
termine what specifically causes these higher a-wave amplitudes in
rodTsc1−/− mice. Interestingly, c-wave amplitudes, which reflect in
part RPE health, did not differ between rodTsc1−/− mice and
controls (SI Appendix, Fig. S4D) (20). Here, higher retinal lactate
levels may have benefited a sick RPE (15, 20). Overall, the data
indicates that loss of Tsc1 in rods leads to a slow progressive
disease, except for areas where advanced pathologies precipitate.
To confirm that GA was not caused by aberrant CRE
recombinase expression in the RPE, we stained RPE flat mounts
for p-S6. While occasional p-S6 positive cells were seen in both
rodTsc1−/− mice and controls at 2M (SI Appendix, Fig. S5A), we
did not find CRE recombinase expression in p-S6–positive cells
(SI Appendix, Fig. S5B). Additionally, the number of p-S6–positive
cells increased dramatically with age (SI Appendix, Fig. S5 A and
C). This increase likely reflects an increase in the number of sick
Fig. 1. Expression levels of PKM2 and HK2 are increased PRs of AMD patients. (A) Immunohistochemistry (IHC) showing increased expression of PKM2 and
HK2 (purple) on retinal cross-sections. Increased expression is seen throughout the PR layer of AMD patients and particularly in cone inner segments (arrows)
and cone pedicles (arrowheads). Dotted lines demark some of the cone inner segments in nondiseased individuals. Enzymatic reaction for IHC was 6 min,
except for the second panel of a nondiseased individual with the PKM2 antibody (30 min.; all diseased sections and all nondiseased sections in A are from the
same retina, respectively; F: female of age indicated in years). (Scale bar: 45 μm.) (B) Immunofluorescence for p-S6 in 2M-old mice of genotypes indicated (red;
blue nuclear DAPI). (Scale bar: 50 μm.) (A and B) GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform layer; IS, inner segments; ONL, outer
nuclear layer; OS, outer segments. (C) Quantification of Western blots for p-S6 and PKM2 with retinas from 2M-old mice (n = 3) of genotypes indicated. On
Top are representative Western images for each protein plus the actin control Western. Results are shown as mean ± SEM (**P < 0.01, ****P < 0.0001). (D and
E) Measurements of retinal lactate (D) and NADPH (E ) levels at 2M of genotypes indicated (n = 4 for lactate and n = 8 for NADPH). Results are shown as
mean ± SEM (*P < 0.05, **P < 0.01).
13096 | www.pnas.org/cgi/doi/10.1073/pnas.2000339117 Cheng et al.
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RPE cells in rodTsc1−/− mice as increased mTORC1 activity in the
RPE has been associated with RPE dysfunction, senescence, and
cell loss (35–37). Moreover, a recent study that deleted Tsc1 from
all RPE cells did not report any advanced AMD pathologies (37).
rodTsc1−/− Mice Also Display Early Disease Features. The metabolic
demands of PRs have been proposed to contribute to lipoprotein
accumulation and drusen formation (8). To determine if the
metabolic changes induced in PRs also contribute to lipoprotein
accumulation, we analyzed the distribution of ApoB and ApoE
at the BrM. We found accumulation of both lipoproteins at the
RPE basal lamina and BrM, independent of any advanced pa-
thology (SI Appendix, Fig. S6A). Electron microscopy (EM)
analyses revealed neutral lipids within the BrM, as well as basal
laminar deposits and thickened BrM in areas of GA (SI Ap-
pendix, Fig. S6B). However, drusen-like deposits were not seen;
rather, basal mounds were quite common (SI Appendix, Fig. S6C).
Additionally, we found increased autofluorescence in the RPE of
rodTsc1−/− mice, indicative of increased lipofuscin accumulation
(SI Appendix, Fig. S6D).
The complement system plays an important role in AMD
pathogenesis (3). In particular, C3 activation is thought to con-
tribute to RPE atrophy and GA (3). We found a uniform down-
regulation of C3 at the BrM and a uniform up-regulation of CFH
in rodTsc1−/− mice (SI Appendix, Fig. S6A). In all, the findings
show that these early disease features, which are induced by
activation of mTORC1 in rods, occur uniformly across the tissue
independent of the presence of any advanced pathology.
AMD-Like Pathologies Are Dependent on the Dose of Activated
mTORC1. To test the requirement of mTORC1 to the patholo-
gies seen, we generated mice with simultaneous deletion of Tsc1
and the mTORC1 adaptor protein Raptor (referred to rodTsc1−/−
rodRaptor−/− mice). Fundus imaging reveled no pathology, except
for the accumulation of microglia in 76% of mice aged between
12M and 18M (Fig. 4 A and B). Even heterozygous Raptor mice
(rodTsc1−/− rodRaptor+/−) did not develop any GA or neovascular
pathologies by 12M (Fig. 4B). However, retinal folds were pre-
sent, albeit at lower frequency. The absence of any severe pa-
thology was in line with the quantification of polynucleated RPE
cells and RPE cell size, which revealed no substantial difference
among these lines at 12M (Fig. 4C). Western blot analyses for
p-S6 and PKM2 confirmed the reduction in mTORC1 activity
(Fig. 4E). Interestingly, while p-S6 levels in rodTsc1−/− rodRap-
tor+/− showed a dose-dependent decline when compared to in
rodTsc1−/− mice, PKM2 levels remained similar to PKM2 levels in
rodTsc1−/−(compare Fig. 4D with Fig. 1C). In contrast, lactate
and NADPH levels remained at the levels of Cre– controls in
heterozygous rodTsc1−/− rodRaptor+/− mice (Fig. 4 E and F). To
determine to which extend this affected the early pathologies, we
reanalyzed the accumulation of ApoB, ApoE, C3, and CFH.
While accumulation of these markers was restored to normal in
rodTsc1−/− rodRaptor−/− mice, heterozygous rodTsc1−/− rodRap-
tor+/− mice displayed a more intermediate phenotype (Fig. 4G).
ApoB showed almost no accumulation while ApoE accumula-
tion was similar to that seen in rodTsc1−/− mice. Similarly, CFH
showed very little accumulation, and C3 was substantially re-
duced. The data suggest that the development of early and late
pathologies is driven in a dose-dependent manner by increased
mTORC1 activity. The extent to which alterations in the ex-
change of lactate and glucose between PRs and the RPE (20)
contribute to advanced pathologies remains to be investigated.
RPE Phagocytosis Is Perturbed in rodTsc1−/− Mice. Impaired RPE
lysosomal activity has been associated with AMD (38–40). The
uniform nature of RPE cell stress led us to investigate if POS
clearance was perturbed in the rodTsc1−/− mice. Since shedding
of rod POSs is circadian, clearance can be monitored over time
on RPE flat mounts stained for the rhodopsin protein. We found
that rod POS clearance was already significantly slowed at 2M in
Fig. 2. Aged rodTsc1−/− mice develop GA and neovascular pathologies. (A) Representative fundus images of littermate controls (Top Row) and rodTsc1−/− mice
(Bottom Row) at ages indicated. (B) Representative fundus fluorescein angiography (FFA) (Bottom Row) images with corresponding fundus image (Top Row)
at 18M of genotypes indicated. rodTsc1+/+ mice show occasionally some microglia accumulation while all rodTsc1+/− mice show microglia accumulation (ar-
rowheads). rodTsc1−/− mice develop retinal folds (arrows), GA (as indicated), and neovascular pathologies (dotted line). (C) Percentage distribution of phe-
notypes explained in B in rodTsc1−/− mice at indicated ages. The last two bars show control mice where only microglia accumulation is seen. Bars show
percentage ± margin of error (M.O.E.). Numbers in parentheses: number of mice analyzed (M, months).
Cheng et al. PNAS | June 9, 2020 | vol. 117 | no. 23 | 13097
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Fig. 3. Histological analyses of advanced AMD-like pathologies. (A) RPE and corresponding retinal flat mount of the same eye, showing autofluorescent RPE
cells and the corresponding area with retinal folds marked with the letter b, and an area of GA and corresponding PR atrophy marked with the letter c. RPE
whole mount is shown in the Left Half, and the corresponding retina in the Right Half of the panel. (Scale bar: 300 μm.) (B) Higher magnification of the region
in A marked with letter b showing autofluorescent RPE cells (arrowhead: Left) that correspond to retinal folds (arrowhead: Middle). Right shows higher
magnification of a fold (different eye) with Iba-1 staining (red) marking microglia (arrows). (Scale bars: 50 μm.) (C) Higher magnification of area of GA marked
in A with the letter c showing in gray scales loss of RPE cells (Left) and retinal PRs (Right; PR side up showing reduced nuclear DAPI density). Note that no folds
are visible in the are of GA in A (letter c), meaning that folds are not required for the formation of GA. (Scale bar: 50 μm.) Colors in A–C are as indicated by
labels in panels. Annotation of colors for A is indicated in the first two images of B (blue, nuclear DAPI; green, autofluorescence [AF] or cone sheets marked by
peanut agglutinin lectin [PNA]; red, RPE boundaries marked by ZO1, cones marked by cone arrestin [CA] or microglia marked by Iba-1). (D) Semithin section
through intermediate stage of GA showing RPE atrophy with PRs still present. No fold is present in this area of RPE atrophy (image size: ∼100 μm). (E)
Consecutive OCT images through area of GA identified by fundus (same eye as shown in Fig. 2 A and B: 18M with GA), showing collapse (between ar-
rowheads) of the outer nuclear layer (ONL) (between dotted lines). (F) Semithin sections of eye with GA shown in E showing multilayered RPE (white asterisk),
RPE migration into the retinal proper (arrow), RPE atrophy (between arrowheads), and retinal angiogenesis (red arrows). As PRs die, retinal folds flatten if
they overlap with areas of GA. Reminiscence of retinal folds is indicated by dotted lines. (Scale bars: 20 μm.) (G) RPE polynucleation and hypertrophy analyses.
Top shows representative RPE image of cell boundaries marked by ZO1 (red signal) used for quantification analyses with output from the IMARIS software on
the Right to identify cell shape, size, and nuclei (blue signal, nuclear DAPI). Bottom shows quantification of RPE polynucleation (Left) and distribution of RPE
cell size (Right). Bars show mean ± SEM (n = 4 RPE flat mounts; *P < 0.05). (Scale bar, 10 μm.)
13098 | www.pnas.org/cgi/doi/10.1073/pnas.2000339117 Cheng et al.
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rodTsc1−/− mice and was rescued in rodTsc1−/− rodRaptor−/− mice,
indicating that the effect was due to increased mTORC1 activity
in rods (Fig. 5 A–C).
POSs are rich in lipids (11, 41), and mTORC1 is known to
regulate lipid synthesis (24, 25). To determine a cause for the
delayed POS clearance by the RPE, we profiled the retinal lipid
composition of rodTsc1−/− mice. We found an approximately three-
fold decrease in di-DHA (44:12) containing phosphatidylethanol-
amine (PE) and phosphatidylcholine (PC) lipids in total retinal
(Fig. 5D) and POS preparations (Fig. 5E). To test if this drop in
di-DHA PE and PC lipids contributes to the delay in POS clear-
ance, we fed rodTsc1−/− mice a diet enriched with 2% DHA. The
2% value was based on a study that showed a beneficial effect with
DHA supplementation on delaying disease progression in humans
(42). Feeding rodTsc1−/− mice a 2% DHA-enriched diet from
weaning onwards improved POS clearance at 2M (Fig. 5F). To
test if delayed POS clearance can also be improved once the delay
has occurred, we fed 6M-old rodTsc1−/− mice the DHA-enriched
diet for 2 wk. This had an even more pronounced effect as POS
clearance was more affected at 6M (Fig. 5G). To determine if
dietary DHA also affected overall RPE health, we kept mice on
the DHA diet from weaning onwards until 6M. This reduced the
percentage of polynucleated RPE cells (Fig. 4H), improved fundus
pathologies (Fig. 5I), prevented the accumulation of ApoB, ApoE,
Fig. 4. AMD-like pathologies are dependent on the dose of activated mTORC1. (A) Representative littermate fundus images of rodTsc1+/+ rodRaptor+/+ (Top),
rodTsc1−/− rodRaptor+/− (Middle), and rodTsc1−/− rodRaptor−/− (Bottom) mice at ages indicated. Fundus of rodTsc1−/− are shown in Fig. 2 and SI Appendix, Fig. S2.
(M, months). (B) Percentage distribution of retinal pathologies scored with mice between 12M and 18M of age of genotypes indicated. rodTsc1+/+ are shown in
Fig. 2C. The graph shows the percentage ± M.O.E. Numbers in parentheses, number of mice analyzed. (C) Analyses of RPE polynucleation and RPE hyper-
trophy at 12M of genotypes indicated. Bars show mean ± SEM (n = 4 mice). (D) Quantification of retinal PKM2 (white) and p-S6 (gray) levels performed by
Western blot in 2M-old mice of genotypes indicated. Bars show mean ± SEM (n = 3 mice) (*P < 0.05, **P < 0.01, ****P < 0.0001). (E and F) Retinal lactate (E)
and NADPH (F) levels at 2M of age of genotypes indicated. Bars show mean ± SEM (n = 4 for lactate and n = 7 for NADPH; n.s.: not significant). (G) Im-
munofluorescence for ApoB, ApoE, C3 and CFH (green signal) on retinal sections of 12M-old mice of genotypes indicated. Higher magnification of the region
between arrowheads is shown on Top of each panel. Blue, nuclear DAPI; red, peanut agglutinin lectin to detect cone segment; magenta, ZO1 to visualize RPE
in ApoE and C3 panels or Phalloidin to visualize RPE in ApoB and CFH panels. Images are representative of three independent experiments with three
different animals. (Scale bars: 20 μm.)
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and CFH, and restored C3 expression (Fig. 5J). Differences in
RPE hypertrophy were not evident, likely because, in younger
mice, hypertrophy is not as pronounced yet. None of 12 DHA-fed
mice (n = 12) developed any GA by 6M while one out of six mice
on the control diet did. Interestingly, reprofiling of the retinal
lipids after 10 wk of DHA feeding revealed that levels of di-DHA
containing PE and PC lipids were not restored. This suggests that
DHA must have acted directly on the RPE to improve overall
PRE health (Fig. 5K). In all, the data indicated that activated
mTORC1 in rods affects the retinal lipid composition, which af-
fects overall RPE health.
Cones Contribute Differently than Rods to Disease. Differences in
the metabolic needs of rods and cones have been proposed to
contribute to different kinds of deposits (8, 14). To more closely
mimic the human retina outside the fovea and study the con-
tribution of cones to advanced pathologies, we generated a line
with a cone-specific deletion of Tsc1 (coneTsc1−/−) and one with a
rod-and-cone deletion (cone&rodTsc1−/−). Funduscopy and angi-
ography revealed that coneTsc1−/− mice develop similar pathol-
ogies without the formation of retinal folds (Fig. 6A). Combining
the metabolic changes in rods and cones did not increase the
overall frequency of advanced pathologies by 12M. However,
advanced pathologies started to occur already at 4M (Fig. 6A).
Choroidal neovascular pathologies in coneTsc1−/− mice were easier
to identify on RPE flat mounts when compared to rodTsc1−/− mice
(Fig. 6B). coneTsc1−/− and cone&rodTsc1−/− mice also developed
Fig. 5. RPE digestion of POSs is perturbed in rodTsc1−/− mice. (A) Representative immunofluorescence images of RPE whole mounts from 2M-old rodTsc1−/− mice at
time of day indicated showing delayed POS clearance by RPE cells (Bottom Row) when compared to control mice (Top Row). POSs are shown in green stained for
RHODOPSIN while RPE cell boundaries are shown in red stained for ZO1 expression. (Scale bars: 10 μm.) (B) Quantification of the number of Rho-positive dots per
RPE cell over the course of the day from 2M-old mice of genotypes indicated, obtained from immunofluorescence images as shown in A. Bars show mean ± SEM
(n = 6–8 RPE flat mounts; **P < 0.01; ****P < 0.0001). (C) Delay of POS clearance shown as percentage of remaining dots 3 h after peak shedding (ratio between
11 AM and 8 AM) in 2M-old mice of genotypes indicated. Bars showmean ± SEM (n = 6–8 RPE flat mounts; ***P < 0.001; ****P < 0.0001). (D) Relative percentage
of di-DHA PE (44:12) and PC (44:12) lipids from total retinal extracts of genotypes indicated at 2M. Bars show mean ± SEM (n = 6–9 mice, two retinas per mouse;
****P < 0.0001). (E) Same as in Dwith purified POSs pooled from six retinas per genotype. (F) POS clearance shown as percentage of remaining dots 3 h after peak
shedding (ratio between 11 AM and 8 AM) in 2M-old mice that were fed a DHA or control diet between weaning to 2M. Shown are mean ± SEM (n = 6 RPE flat
mounts; *P < 0.05; **P < 0.01; ns: not siginificant). (G) Same as in F with 6M-old mice that were fed a DHA diet for only 2 wk. Shown are mean ± SEM (n = 6 RPE
flat mounts; **P < 0.01; ****P < 0.0001). (H) RPE polynucleation (Left) and hypertrophy (Right) analyses of rodTsc1−/− mice that were fed a DHA or control diet
between weaning to 6M. Bars are mean ± SEM (n = 6 mice RPE flat mounts; *P < 0.05; **P < 0.01). (I) Representative fundus images of rodTsc1−/− mice on control
(Top Row) or DHA (Bottom Row) diet from weaning onwards until time point indicated in panel (M, months). (J) AMD-related markers on retinal sections of
rodTsc1−/−mice that were fed a DHA or control diet betweenweaning to 6M. Proteins of interest indicated on top are shown in green. Highermagnification of the
region between arrowheads is shown on Top of each panel (blue, nuclear DAPI; red, cone sheets marked peanut agglutinin lectin [PNA]; magenta, ZO1 marking
RPE boundaries for ApoE and C3 panels and Phalloidin marking boundaries for ApoB and CFH panels). (Scale bars: 20 μm.) GCL, ganglion cell layer; RPE, retinal-
pigmented epithelium. Images are representatives of three independent experiments on three different animals per genotype. (K) Same experiment as in D after
feeding mice a DHA diet from weaning onwards for 10 wk. Bars show mean ± SEM (n = 3 mice, two retinas per mouse; *P < 0.05; **P < 0.01; ****P < 0.0001).
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large drusen-like deposits that were positive for ApoE (Fig. 6 C
and D). Such large deposits were not seen in rodTsc1−/− mice. EM
analyses revealed that loss of Tsc1 in cones was sufficient to cause
accumulation of small lipoprotein vesicles, reminiscent of basal
linear deposits, within the BrM (Fig. 6E), which may explain the
difference in deposit size. Finally, areas of GA were generally
larger in cone&rodTsc1−/− mice when compared with rodTsc1−/− or
coneTsc1−/− mice (Fig. 6F). This allowed visualization of ongoing
RPE atrophy by terminal deoxynucleotidyltransferase-mediated
dUTP nick end labeling (TUNEL) (Fig. 5F). All other patholo-
gies, such as uniform accumulation of lipoproteins and changes in
C3 and CFH expression, were similar between all three lines, with
the coneTsc1−/− mice displaying the least pronounced changes (SI
Appendix, Fig. S7 A and B). Rod POS clearance was also affected
in coneTsc1−/− mice, suggesting that our previous findings were not
due to an increase in the shedding rate of rod POSs, since loss of
Tsc1 in cones affects rod POS clearance, too. (SI Appendix, Fig.
S7C). Di-DHA PE lipids were also significantly reduced in
coneTsc1−/− mice (SI Appendix, Fig. S7D), suggesting that any re-
duction in di-DHA PE lipids may affect RPE health. Interestingly,
activation of mTORC1 upon loss of Tsc1 was stronger in cones
when compared to rods (SI Appendix, Fig. S7E) (26). How this
affects cell metabolism remains to be investigated. However, this
might in part explain how the relatively low number of cones in
mouse might still be able to cause advanced pathologies. In all, the
data show that there are distinct mechanisms between rods and
cones that contributed to advanced AMD pathologies, which is in
line with the findings in humans (8, 14).
Discussion
Age-related macular degeneration is as a multifactorial disease
of unclear etiology. Here, we show that altering the metabolic
profile of PRs is sufficient to cause 1) changes in ApoB, ApoE,
C3, and CFH accumulation at the BrM, 2) formation of drusen-
like deposits, and 3) GA and neovascular pathologies. The fact
that these mice develop advanced AMD-like pathologies at the
same frequency as humans, and that pathologies can be ame-
liorated by dietary DHA supplementation, suggests that our
mouse model may be a valuable tool to study the progression of
human AMD. How does our data complement the current un-
derstanding of AMD disease progression?
Histopathological analyses indicate that the early disease stages
start with the formation of a lipid wall at the choroid–retinal blood
barrier, affecting primarily the BrM and the RPE basal lamina (oil
spill model) (8, 14). This likely impedes the transfer of hydrophilic
molecules such as glucose from the choroidal circulation to PRs.
From our studies on retinitis pigmentosa, we know that PRs re-
spond to a reduction in glucose availability by increasing the ex-
pression of HK2 and PKM2 through increased mTORC1 activity
(18, 21, 22, 43). This helps improve glucose uptake and to redirect
a larger percentage of the remaining glucose into the anabolic
pathway, which helps maintain POS growth (18, 21, 22, 43). In-
deed, we found increased expression of PKM2 and HK2 in PRs of
AMD patients. Additionally, PKM2 autoantibodies have been
found in AMD patients, independent of the disease stage (30),
suggesting that this PR adaptive response is an early reaction of
PRs to the formation of the initial lipid wall. By activating
mTORC1 in PRs, we thus mimic the adaptive response of PRs to
the formation of the initial lipid wall. Since lipid accumulation
occurs in all of our models, the metabolic adaptations by PRs
further contribute to drusen growth. However, large drusen (>60
μm in diameter) as in humans were not seen in our mice. This is
likely because the initial lipid wall, which serves as a foundation
for further drusen growth, is not present at the start of our ex-
periments. Additionally, large soft-drusen are preferentially asso-
ciated with the metabolism of foveal cones (8, 14), which are
absent in mouse. Based on our findings, we propose a two-stage
process of AMD pathogenesis. In the first stage (SI Appendix, Fig.
S8), environmental and/or genetic risk factors, such as diet, exer-
cise, and metabolic risk genes, lead to the formation of a lipid wall
at the BrM, as proposed by others (8, 44, 45). In the second stage,
PR adaptations to the reduction in nutrient transfer further en-
hance lipid accumulation, while also causing excessive RPE stress.
This causes RPE atrophy, GA, and neovascular pathologies, as
seen in our mouse models and in humans (15, 39, 40, 46). While
this second stage continues to be affected by the same risk factors
as the first stage, other risk genes, such as the ones of the innate
immune system like C3 and CFH, increase the risk for disease
progression (3, 8, 44, 45). The involvement of PRs in disease
pathogenesis, which is also supported by a recent RNA sequencing
study (47), may also explain why AMD preferentially affects the
macular region; it is the area of highest PR density.
The absence of drusen-like deposits in rodTsc1−/− mice sug-
gests that drusen are not required for RPE atrophy or neo-
vascular pathologies to occur. This suggests that there are PR-
intrinsic changes that affect RPE health besides the aggregation
of lipoproteins at the BrM. In this regard, we found the drop in
di-DHA PE and PC lipid species interesting. DHA-containing
phospholipids provide an optimal lipid environment for photo-
transduction (48) and neuroprotective functions (49, 50). In the
retina, these phospholipids account for approximately 15 to 20%
PC, 20 to 35% PE, and 30 to 50% PS, with POSs that are
phagocytosed daily by the RPE having greater levels (51). The
finding that dietary DHA supplementation did not restore reti-
nal di-DHA PE and PC levels suggests that the enzymes required
for the synthesis of these lipids were down-regulated as a result
of increased mTORC1 activity. mTORC1 is a key regulator of
lipid metabolism, in part through regulation of the sterol regu-
latory element-binding protein 1 and 2 (SREBP-1 and SREBP-2)
(25). Further support for altered lipid metabolism comes from a
human study that profiled total retinal and RPE/choroid fatty
acids. The study found that total retinal and RPE/choroid DHA
levels in humans with AMD were reduced by ∼29% and ∼45%,
respectively (52). Together, these findings may explain why,
contrary to the prediction of many epidemiological studies (9,
10), the AREDS2 study (53) did not find an association between
risk reduction and DHA supplementation. If, in AMD patients,
DHA acts directly on the RPE to reduce RPE stress, then the
nutritional intake of DHA may need to be high in order to benefit
the RPE: in particular, the RPE opposing foveal cones. This is
because rods siphon off most of the free DHA that enters the eye
(11). Additionally, if the RPE prefers these two specific di-DHA
phospholipids as a DHA source for proper cellular function, then
exogenous levels that are not PR-derived may need to be higher in
order to have a beneficial effect on RPE health. Our study was
based on a study that showed a protective effect with five times
higher levels of omega-3 fatty acids (42) than the AREDS2 study.
It is important to note that we do not think that the reduction in
these di-DHA phospholipid species is the sole underlying cause
for disease progression; rather, by reducing overall RPE stress,
they reduce the risk for progression. The role of these two di-
DHA phospholipids in RPE health remains to be investigated.
Similarly, how DHA supplementation reduced RPE stress re-
mains to be determined. However, DHA serves as a precursor for
the synthesis of RPE-derived neuroprotectin D1, and PE lipids
have been found to positively regulate autophagy and reduce age-
related oxidative stress and cell death (49–51). Additionally, DHA
has been found to have antiinflammatory properties regulating
many aspects of the immune system (54). Thus, the protective
effect of DHA seen here could be occurring at multiple levels.
The finding that heterozygous Raptor mice with intermediate
mTORC1 activity did not develop advanced pathologies suggests
that these pathologies are driven in a dose-dependent manner by
mTORC1. Consistent with this, some of the early pathologies
displayed a more intermediate phenotype. Interestingly, in het-
erozygous Raptor mice (rodTsc1−/− rodRaptor+/−), PKM2 levels
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remained high while lactate and NADPH levels dropped to Cre–
control levels. Therefore, it remains to be investigated to which
extent changes in the energy ecosystem between PRs and RPE
contribute to advanced pathologies (15, 20, 55, 56). However, it
is important to note that the circumstances in which PRs find
themselves in AMD retinas and in our mouse model differ since
Fig. 6. Cones contribute differently than rods to disease. (A) Representative fundus images at 12M (Top) and percentage distribution of pathologies (graphs
Below: microglia accumulation, Top Left; retinal folds, Top Right; GA, Bottom Left; angiogenesis, Bottom Right) seen over time of genotypes indicated (M,
months). Graphs show percentage ± M.O.E. (n = 10–15 mice). (B) coneTsc1−/− mouse at 12M showing PR atrophy on retinal flat mount with retinal microglia
migrating to the site of injury (Left) and choroidal neovascularization on corresponding RPE flat mount of the same region (Right). Eye corresponds to fundus
of coneTsc1−/− shown in A. (Scale bar: 50 μm.) Colors are as indicated by labels in panels (blue, nuclear DAPI; green, cone sheets marked by peanut agglutinin
lectin [PNA] or vascular marked with lectin B4 [Lectin B4]; red, microglia marked by Iba1 or RPE boundaries marked by ZO1). (C) Semithin section image of coneTsc1−/−
mouse at 12M showing large drusen-like deposit (see Inset ). (Below) EM image of deposit and to the Right higher magnification of boxed area in EM image. The BrM
is marked by a double arrow. Arrowheads mark RPE basal fold, and arrows mark translucent lipid vesicles. (D) Large drusen-like deposits marked with letter D
in rod&coneTsc1−/− mouse at 12M showing accumulation of ApoE (red signal). Enlarged area between arrowheads of Left image is shown to the Right in bright
field. (Scale bars: 20 μm.) Colors are as indicated by labels in panel (blue, nuclear DAPI; green, cone sheets marked by peanut agglutinin lectin [PNA]; red,
deposits positive for ApoE). (E) EM images of coneTsc1−/− mouse at 12M showing basal mounds (asterisk, larger mound; arrowheads, micro mounds), lipo-
protein vesicles in the BrM (arrows), dysmorphic mitochondria (M), and membranous discs (MD). (Right) Enlarged area of basal mound marked with asterisk
on the left showing lipoprotein vesicles in BrM (arrows). (F) Large GA area in rod&coneTsc1−/− mouse at 12M showing TUNEL-positive RPE cells. Left panel shows
RPE whole mount, while Right panel shows higher magnification of GA area surrounded by dysmorphic RPE cells and TUNEL-positive nuclei (arrowheads).
Inset shows higher magnification of TUNEL-positive nuclei. (Scale bars: Left, 300 μm; Right, 15 μm.) Colors are as indicated by labels in panels (blue, nuclear
DAPI; green, autofluorescence [AF] in Left panel and apoptosis marked by TUNEL in Right panel; red, RPE boundaries marked by Phalloidin).
13102 | www.pnas.org/cgi/doi/10.1073/pnas.2000339117 Cheng et al.
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glucose is not limiting in our experiments due to the absence of a
lipid wall. Nonetheless, our mice develop the same intermediate
and advanced pathologies as seen in humans with AMD. This
suggests that changes in the exchange of glucose and lactate be-
tween the retina and RPE are less likely to be the driving force for
the development of advanced pathologies as these differ between
our mouse models and AMD patients. Rather, the data suggest
that gene expression changes that accompany the adaptations to a
glucose shortage cause disease progression (e.g., down-regulation
of enzymes that cause drop in di-DHA phospholipids). In line with
this, DHA feeding was able to ameliorate most pathologies. While
we did not measure lactate and NADPH levels in DHA-fed
rodTSC1−/− mice, one would not expect that this feeding regimen
would restore lactate and NADPH levels to Cre– control levels.
The disruption in the energy ecosystem between the PRs and the
RPE in rodTSC1−/− mice is thus unlikely to be the driving force for
the pathologies seen in these mice. It remains to be investigated
which changes downstream of mTORC1 lead to disease progres-
sion in our mouse models. Identifying these changes is important
since these changes may not require high mTORC1 activity in
humans to cause disease. Once identified, they would allow us to
study how much our mouse model parallels the human disease.
Moreover, it might also offer new therapeutic targets to delay
disease progression in humans if such changes are confirmed in
humans. There are likely several changes that are required to
occur, either simultaneously or sequentially, in order for advanced
pathologies to develop. This means that preventing one of the
changes to occur might suffice to delay disease progression. Be-
cause advanced pathologies are dependent on the dose of acti-
vated mTORC1 in mouse, one might also considering decreasing
mTORC1 activity. In this regard, mTORC1 inhibitors have al-
ready been used in several clinical trials on patients with advanced
AMD (57, 58). However, these trials reported either no effect or
even some adverse effects resulting in reduced vision. The likely
explanation for this is that inhibiting mTORC1 activity in patients
with advanced disease affects PR survival as mTORC1 activity is
required to help PRs adapt to the nutrient stress that they are
experiencing due to lost or dysfunctional RPE cells. We previously
reported that mTORC1 activity is required for the survival of
metabolically stressed PRs (18, 22, 43), in particular in areas of
GA (26). Reducing mTORC1 activity during the early disease
stages might be more beneficial. In line with this, a retrospective
study found that the antidiabetic drug Metformin, which reduces
mTORC1 activity by activating AMP kinase, reduces the risk for
developing AMD (59). More studies are needed to determine the
correct time window and dose of mTORC1 inhibition in humans.
Additionally, identifying the downstream factors that lead to ad-
vanced disease may allow one to block disease progression without
preventing PRs from adapting to the nutrient shortage. In all, our
findings complement the current model of AMD pathogenesis,
showing in mouse that activation of mTORC1 in PRs leads to the
development of a complex pathology that affects overall RPE
health over time.
Materials and Methods
All procedures involving animals were in compliance with the Association for
Research in Vision and Ophthalmology Statement for the Use of Animals in
Ophthalmic and Vision Research and were approved by the Institutional
Animal Care and Use Committees of the University of Massachusetts Medical
School. Procurement of human samples by B.P.H. was approved by the
Partners Institutional Review Board. The Institutional Review Board of the
University of Massachusetts issued a waiver to C.P. to work with deidentified
human tissue sections since he was not involved in procuring human tissue.
Similarly, the Institutional Review Board of the University of Connecticut
issued a waiver to R.N.K. to work with deidentified tissue samples. Tissue
sample contributed by R.N.K. was procured under an approved protocol by
Institutional Review Board of the University of Connecticut through the
University of ConnecticutHealthCenter. R.N.K. receivedonly deidentified tissue
that was contributed to this study. Extensive materials and methods regarding
all procedures are provided in SI Appendix, Materials and Methods.
Data Availability. All data and experimental parameters related to this paper
are available in the main text and SI Appendix.
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